Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
THLD's Cash-to-Debt is ranked higher than
91% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. THLD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
THLD' s Cash-to-Debt Range Over the Past 10 Years
Min: 17.14  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
THLD's Interest Coverage is ranked higher than
93% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. THLD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
THLD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: -3.92
Beneish M-Score: 9.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 47.24
THLD's Operating Margin % is ranked higher than
95% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. THLD: 47.24 )
Ranked among companies with meaningful Operating Margin % only.
THLD' s Operating Margin % Range Over the Past 10 Years
Min: -48445.16  Med: -820.92 Max: 47.24
Current: 47.24
-48445.16
47.24
Net Margin % 70.88
THLD's Net Margin % is ranked higher than
96% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. THLD: 70.88 )
Ranked among companies with meaningful Net Margin % only.
THLD' s Net Margin % Range Over the Past 10 Years
Min: -41375.81  Med: -1241.37 Max: 70.88
Current: 70.88
-41375.81
70.88
ROE % 260.69
THLD's ROE % is ranked higher than
99% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. THLD: 260.69 )
Ranked among companies with meaningful ROE % only.
THLD' s ROE % Range Over the Past 10 Years
Min: -544.3  Med: -96.09 Max: 519.53
Current: 260.69
-544.3
519.53
ROA % 109.78
THLD's ROA % is ranked higher than
99% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. THLD: 109.78 )
Ranked among companies with meaningful ROA % only.
THLD' s ROA % Range Over the Past 10 Years
Min: -132.78  Med: -67.3 Max: 109.78
Current: 109.78
-132.78
109.78
ROC (Joel Greenblatt) % 12035.90
THLD's ROC (Joel Greenblatt) % is ranked higher than
99% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. THLD: 12035.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
THLD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7379.85  Med: -2750.54 Max: 12035.9
Current: 12035.9
-7379.85
12035.9
3-Year Revenue Growth Rate 113.20
THLD's 3-Year Revenue Growth Rate is ranked higher than
94% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. THLD: 113.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
THLD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 514.5
Current: 113.2
0
514.5
GuruFocus has detected 2 Warning Signs with Threshold Pharmaceuticals Inc $THLD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» THLD's 10-Y Financials

Financials (Next Earnings Date: 2017-03-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

THLD Guru Trades in Q1 2016

Jim Simons 1,016,764 sh (+55.55%)
» More
Q2 2016

THLD Guru Trades in Q2 2016

First Eagle Investment 3,199,433 sh (New)
Jim Simons 774,763 sh (-23.80%)
» More
Q3 2016

THLD Guru Trades in Q3 2016

Charles Brandes 140,000 sh (New)
First Eagle Investment 5,974,802 sh (+86.75%)
Jim Simons 690,399 sh (-10.89%)
» More
Q4 2016

THLD Guru Trades in Q4 2016

First Eagle Investment 7,093,802 sh (+18.73%)
Charles Brandes Sold Out
Jim Simons 623,399 sh (-9.70%)
» More
» Details

Insider Trades

Latest Guru Trades with THLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CUR, NAS:ZSAN, OTCPK:PTGEF, OTCPK:DYAI, OTCPK:GRPOF, NAS:CLBS, NAS:CYTR, AMEX:AMPE, OTCPK:GBLX, OTCPK:PBYA, NAS:TRIL, OTCPK:LVCLF, OTCPK:BLEVF, NAS:XBIO, OTCPK:FENCF, NAS:DMPI, NAS:CYTX, OTCPK:VBIO, NAS:PBMD, NAS:TPIV » details
Traded in other countries:NZW1.Germany,
Threshold Pharmaceuticals Inc is a biotechnology company. It is engaged in discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer.

Threshold Pharmaceuticals Inc is a Delaware corporation incorporated on October 17, 2001. It's a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of these tissues is characterized by hypoxia or lack of oxygen. Its hypoxia activated prodrug ("HAP") product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. Its focus is on product candidates for the treatment of patients with cancer. Its clinical development efforts are currently engaged in TH-302, for which it entered a license and co-development agreement with Merck KGaA for development and commercialization. TH-302 is a novel drug candidate that is activated under severe hypoxic conditions and was designed to specifically target the severe hypoxic regions that are believed to be present in all solid tumors and hematologic malignancies. The production of TH-302 employs small molecule organic chemistry procedures that are standard for the pharmaceutical industry. It currently relies on contract manufacturers for the manufacture of active pharmaceutical ingredient ("API"), and final drug product of TH-302. Under its license and co-development agreement with Merck KGaA, the Company is dependent on Merck for clinical and commercial supply of TH-302, except for clinical trials for United States approval of TH-302 for soft tissue sarcoma and for any other clinical trials for which it is responsible. For these latter cases, it can obtain clinical supply directly from existing or new suppliers. It currently uses contract manufacturers to manufacture TH-302 API and TH-302 drug product. The commercial sale for pancreatic cancer, TH-302 would compete with Gemzar, marketed by Eli Lilly and Company; Tarceva, marketed by Genentech and Astellas Oncology; Abraxane marketed by Celgene; and FOLFIRINOX. The manufacturing and marketing of its potential products and its ongoing research and development activities are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.

Ratios

vs
industry
vs
history
PE Ratio 1.01
THLD's PE Ratio is ranked higher than
95% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. THLD: 1.01 )
Ranked among companies with meaningful PE Ratio only.
THLD' s PE Ratio Range Over the Past 10 Years
Min: 0.45  Med: 0.97 Max: 55.56
Current: 1.01
0.45
55.56
PE Ratio without NRI 1.01
THLD's PE Ratio without NRI is ranked higher than
96% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. THLD: 1.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
THLD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.45  Med: 0.97 Max: 55.56
Current: 1.01
0.45
55.56
PB Ratio 1.94
THLD's PB Ratio is ranked higher than
74% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. THLD: 1.94 )
Ranked among companies with meaningful PB Ratio only.
THLD' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.91 Max: 66.81
Current: 1.94
0.23
66.81
PS Ratio 0.69
THLD's PS Ratio is ranked higher than
96% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. THLD: 0.69 )
Ranked among companies with meaningful PS Ratio only.
THLD' s PS Ratio Range Over the Past 10 Years
Min: 0.23  Med: 24.93 Max: 6080
Current: 0.69
0.23
6080
EV-to-EBIT 0.49
THLD's EV-to-EBIT is ranked higher than
94% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. THLD: 0.49 )
Ranked among companies with meaningful EV-to-EBIT only.
THLD' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.4  Med: -0.9 Max: 7.3
Current: 0.49
-22.4
7.3
EV-to-EBITDA 0.48
THLD's EV-to-EBITDA is ranked higher than
95% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. THLD: 0.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
THLD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.3  Med: -1 Max: 7
Current: 0.48
-23.3
7
Current Ratio 7.94
THLD's Current Ratio is ranked higher than
78% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. THLD: 7.94 )
Ranked among companies with meaningful Current Ratio only.
THLD' s Current Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.16 Max: 13.48
Current: 7.94
1.48
13.48
Quick Ratio 7.94
THLD's Quick Ratio is ranked higher than
78% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. THLD: 7.94 )
Ranked among companies with meaningful Quick Ratio only.
THLD' s Quick Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.16 Max: 13.48
Current: 7.94
1.48
13.48
Days Sales Outstanding 2.10
THLD's Days Sales Outstanding is ranked higher than
96% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. THLD: 2.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
THLD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.1  Med: 354.13 Max: 972.69
Current: 2.1
2.1
972.69

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.20
THLD's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. THLD: -8.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
THLD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -702.9  Med: -47.8 Max: -8.2
Current: -8.2
-702.9
-8.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.07
THLD's Price-to-Net-Cash is ranked higher than
87% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. THLD: 2.07 )
Ranked among companies with meaningful Price-to-Net-Cash only.
THLD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.45  Med: 2.84 Max: 24.4
Current: 2.07
0.45
24.4
Price-to-Net-Current-Asset-Value 1.94
THLD's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. THLD: 1.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
THLD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.44  Med: 2.77 Max: 24.4
Current: 1.94
0.44
24.4
Price-to-Tangible-Book 1.94
THLD's Price-to-Tangible-Book is ranked higher than
80% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. THLD: 1.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
THLD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.4  Med: 2.5 Max: 13.41
Current: 1.94
0.4
13.41
Price-to-Median-PS-Value 0.03
THLD's Price-to-Median-PS-Value is ranked higher than
99% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. THLD: 0.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
THLD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.87 Max: 58.67
Current: 0.03
0.02
58.67
Price-to-Graham-Number 0.29
THLD's Price-to-Graham-Number is ranked higher than
96% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. THLD: 0.29 )
Ranked among companies with meaningful Price-to-Graham-Number only.
THLD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.18  Med: 0.3 Max: 1.69
Current: 0.29
0.18
1.69
Earnings Yield (Greenblatt) % 202.86
THLD's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. THLD: 202.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
THLD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 13.7  Med: 339.8 Max: 163390.7
Current: 202.86
13.7
163390.7

More Statistics

Revenue (TTM) (Mil) $69.55
EPS (TTM) $ 0.62
Beta3.45
Short Percentage of Float1.17%
52-Week Range $0.21 - 1.48
Shares Outstanding (Mil)71.56

Analyst Estimate

Dec16 Dec17
Revenue (Mil $)
EPS ($) -0.24 -0.31
EPS without NRI ($) -0.24 -0.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for THLD

Headlines

Articles On GuruFocus.com
Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL May 12 2015 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 52,356 Shares Oct 06 2009 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 20,000 Shares Jun 05 2009 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Research Reports Coverage on Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold... Jan 26 2017
Hurry! These 5 Stocks Are About to Break Out Explosively Jan 13 2017
Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424 Dec 19 2016
Is Threshold Pharmaceuticals, Inc. (THLD) A Good Stock To Buy? Dec 12 2016
THRESHOLD PHARMACEUTICALS INC Financials Nov 15 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Nov 15 2016
Merck KGaA expects profit gain from lower development costs Nov 15 2016
Threshold Pharmaceuticals Reports Third Quarter Financial Results Nov 07 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 07 2016
Caris Life Sciences and Threshold Pharmaceuticals Collaborate to Utilize Caris' ADAPT Biotargeting... Oct 25 2016
Caris Life Sciences and Threshold Pharmaceuticals Collaborate to Utilize Caris' ADAPT Biotargeting... Oct 25 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 18 2016
Is Threshold Pharmaceuticals a Buy? (THLD) Oct 03 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Sep 30 2016
Why Investors Are Buzzing About Threshold Pharmaceuticals, Enbridge, Facebook and More Sep 30 2016
COO of Threshold Pharmaceuticals to Resign (THLD) Sep 29 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus... Sep 29 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Sep 29 2016
Key FDA Decisions and Trial Results Coming in the Next 2 Months Sep 14 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Sep 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)